Join
Live feed
·
PRReleasevia Quantisnow
Climb Bio Inc. logo

Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy

ByQuantisnow·Wall Street's wire, on your screen.
CLYM· Climb Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CLYM (Climb Bio Inc.) and more on Quantisnow.